Next Article in Journal
Direct and Competitive Optical Grating Immunosensors for Determination of Fusarium Mycotoxin Zearalenone
Next Article in Special Issue
The Central Effects of Botulinum Toxin in Dystonia and Spasticity
Previous Article in Journal
New Data on Cylindrospermopsin Toxicity
Previous Article in Special Issue
The Effectiveness of Botulinum Toxin Type A (BoNT-A) Treatment in Brazilian Patients with Chronic Post-Stroke Spasticity: Results from the Observational, Multicenter, Prospective BCause Study
Review

Botulinum Toxin in Movement Disorders: An Update

Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Received: 11 November 2020 / Revised: 30 December 2020 / Accepted: 5 January 2021 / Published: 8 January 2021
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies. View Full-Text
Keywords: botulinum toxin; movement disorders; tremors; dystonia; tics; bruxism; restless legs syndrome; Parkinson’s disease; myoclonus; dyskinesia botulinum toxin; movement disorders; tremors; dystonia; tics; bruxism; restless legs syndrome; Parkinson’s disease; myoclonus; dyskinesia
Show Figures

Figure 1

MDPI and ACS Style

Anandan, C.; Jankovic, J. Botulinum Toxin in Movement Disorders: An Update. Toxins 2021, 13, 42. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010042

AMA Style

Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins. 2021; 13(1):42. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010042

Chicago/Turabian Style

Anandan, Charenya; Jankovic, Joseph. 2021. "Botulinum Toxin in Movement Disorders: An Update" Toxins 13, no. 1: 42. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010042

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop